Missing data, liver injury problematic for Otsuka's tolvaptan, FDA reviewers say
This article was originally published in Scrip
Executive Summary
Things are looking pretty rough for Otsuka's tolvaptan heading into a 5 August meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, with agency reviewers finding several problems with the drug's data.